Fresenius Kabi’s EU Biosimilars ‘Lagging Behind Expectations’
COVID-19 Has Hit Impacted Market
Fresenius Kabi is looking to make headway into biosimilars but saw its progress limited by COVID-19 in Q2. Management gave an update on the company’s endeavors during the Q2 earnings call, including key tender victories.
